NASDAQ-GS · traded in Congress
Agios Pharmaceuticals, AGIO
$29.41 +1.14 (+4.03%) Nov 6, 2026
Market value$1.8B
P/E ratio-
Analyst target$37.00
52-week range-
Avg volume1,089,222
Dividend yieldN/A
Chart
Analyst ratings
- 7 buy
- 3 hold
- 0 sell
Low target$32.00
Average target$45.63
High target$74.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $55M | - | $-65M | -117.4% | |
| $45M | - | $-101M | -225.1% | |
| $21M | - | $-99M | -477.7% | |
| $20M | - | $-108M | -541.1% |
Congress trades in AGIO
Members of Congress disclosed 2 transactions in AGIO in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 08/20/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 9/10/2026 filing |
| 03/03/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
